Monitoring and oversight are now scaled based on the actual risks of a trial. Low-risk aspects should not be overburdened with unnecessary bureaucracy.
For the first time, the guideline explicitly addresses digital tools, wearables, and the "chain of custody" for digital data to ensure traceability and reproducibility. under e6
E6(R3) emphasizes building quality into the trial design from the start, rather than relying on retrospective checking. Monitoring and oversight are now scaled based on
The International Council for Harmonisation (ICH) recently finalized the guideline, which entered into force in July 2025. This update represents a major shift toward digital-first, risk-proportional clinical research. E6(R3) emphasizes building quality into the trial design
There is a renewed focus on patient well-being, including expanded transparency in informed consent (e.g., explaining what happens to data if a participant withdraws). 2. OfS Condition E6: Higher Education Safety Quality by Design in Clinical Trials under ICH E6(R3)